StockWatch
·
Services-Offices & Clinics of  Doctors of  Medicine
Quarterly ResultNov 17, 2026, 05:35 PM

Auna Reports 10% 3Q26 FX-Neutral Revenue Growth; Mexico EBITDA Recovers

AI Summary

Auna announced its 3Q26 financial results, reporting a 10% FX-neutral revenue growth to S/1,325 million. The company saw a return to year-over-year Adjusted EBITDA growth in Mexico, but profitability was pressured in Colombia and Peru due to specific headwinds. Leverage improved to 3.5x. Auna also provided a full-year guidance update, reaffirming revenue guidance but revising Adjusted EBITDA outlook to be broadly stable or slightly down year-over-year. Additionally, the Centro Ambulatorio Trecca Public-Private Partnership in Peru entered its construction phase.

Key Highlights

  • Auna reported 3Q26 revenue of S/1,325 million, a 10% increase YoY on an FX-neutral basis.
  • Adjusted EBITDA decreased 4.6% YoY FXN to S/231 million, with margins at 17.5%.
  • Mexico Segment Adjusted EBITDA grew 5% YoY in local currency, marking its first YoY growth in 2026.
  • Colombia Segment Adjusted EBITDA declined 30% YoY in local currency due to adverse medical costs and regulatory price caps.
  • Year-to-date Net Cash from Operating Activities increased 62% YoY to S/713 million.
  • Leverage Ratio improved to 3.5x.
  • The Centro Ambulatorio Trecca Public-Private Partnership in Peru entered its construction phase, expected to be operational by late 2028.
  • Full-year revenue guidance reaffirmed at 10%-14% FX-neutral growth; Adjusted EBITDA outlook revised to broadly stable or slightly down YoY.